ReviewiScience2026
Brain network alterations in autoimmune diseases: Current status and future prospects.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune diseases are frequently associated with neurological and cognitive dysfunction. Advances in neuroimaging and graph theory-based connectomics have enabled investigation of large-scale brain network alterations across autoimmune conditions. This review synthesizes structural and functional network studies in representative diseases, including multiple sclerosis, neuromyelitis optica spectrum disorder, systemic lupus erythematosus, thyroid eye disease, type 1 diabetes mellitus, and inflammatory bowel disease. Across these disorders, studies commonly report reduced global and local efficiency, altered modular organization, and regional hub vulnerability, although findings vary across disease subtype, imaging modality, and analytic methodology. Network alterations are often associated with cognitive impairment and neuropsychiatric symptoms, suggesting potential relevance for understanding disease burden and progression. However, current evidence remains heterogeneous and is derived largely from cross-sectional studies with modest sample sizes. Future longitudinal and standardized multimodal studies are needed to clarify the biological and clinical significance of connectomic alterations in autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.